10-Q: Callan JMB Reports Wider Q3 Loss Amid Rising Costs

Callan JMB Inc. reported a significantly wider net loss for the third quarter and first nine months of 2025, driven by increased operating expenses and costs associated with its new Equity Line of Credit facility.

Summary

• Net loss for the three months ended September 30, 2025, was $(2,731,341), a 239% increase from $(804,987) in the same period of 2024.
• Net loss for the nine months ended September 30, 2025, was $(5,373,327), a 438% increase from $(998,596) in the same period of 2024.
• Revenue for the nine months ended September 30, 2025, decreased by 12% to $4,562,604 from $5,211,665 in the prior year, primarily due to decreased demand for emergency preparedness services.
• Selling, general and administrative expenses surged by 99% to $6,274,343 for the nine months ended September 30, 2025, compared to $3,146,109 in the prior year, largely due to increased consulting, professional fees, and marketing expenses related to the IPO and public company operations.
• Cash used in operating activities for the nine months ended September 30, 2025, was $(3,887,737), a significant decline from $1,263,526 cash provided in the prior year.
• The company completed its initial public offering (IPO) in February 2025, raising approximately $4,700,000 in net proceeds.
• An Equity Line of Credit (ELOC) facility was established on July 24, 2025, allowing the company to sell up to $25.0 million of common stock, with approximately $497,750 raised as of September 30, 2025.
• The ELOC facility resulted in a derivative liability of $624,041 as of September 30, 2025, and related expenses significantly impacted other income/expenses.
• Disclosure controls and procedures were deemed not effective as of September 30, 2025, due to a lack of written documentation for some internal control policies and incomplete segregation of duties.

Sentiment

Score: 2

Explanation: The company reported significantly wider net losses and negative operating cash flow, indicating severe financial challenges. While capital was raised through an IPO and ELOC, the substantial increase in expenses and accumulated deficit, coupled with ineffective internal controls, points to a very negative financial position and outlook.

Positives

• Cash and cash equivalents increased to $2,789,744 as of September 30, 2025, from $2,097,945 at December 31, 2024.
• Gross profit for the three months ended September 30, 2025, increased by 6% to $493,307 compared to $464,445 in the same period of 2024.
• Successfully completed an Initial Public Offering (IPO) in February 2025, generating approximately $4,700,000 in net proceeds.
• Established an Equity Line of Credit (ELOC) facility for up to $25.0 million, providing a potential source of future funding.
• Governmental customer type revenue increased for both the three and nine months ended September 30, 2025, compared to the prior year periods.

Negatives

• Net loss significantly widened by 239% for the three months ended September 30, 2025, to $(2,731,341) and by 438% for the nine months ended September 30, 2025, to $(5,373,327).
• Revenue for the nine months ended September 30, 2025, decreased by 12% to $4,562,604, primarily due to reduced demand for emergency preparedness services.
• Selling, general and administrative expenses nearly doubled, increasing by 99% to $6,274,343 for the nine months ended September 30, 2025, driven by IPO-related and public company costs.
• Operating activities consumed $(3,887,737) in cash for the nine months ended September 30, 2025, a substantial negative shift from cash provided in the prior year.
• A new derivative liability of $624,041 was recognized as of September 30, 2025, related to the ELOC facility, impacting other expenses.
• Accumulated deficit significantly increased to $(7,666,975) as of September 30, 2025, from $(2,293,648) at December 31, 2024.
• Disclosure controls and procedures were concluded to be not effective as of September 30, 2025, citing a lack of written documentation and incomplete segregation of duties.

Risks

• The company's disclosure controls and procedures were not effective as of September 30, 2025, due to a lack of written documentation for some internal control policies and incomplete segregation of duties.
• A significant portion of accounts receivable and revenue is concentrated among a few large customers, making the company vulnerable to their financial health or changes in demand.
• The company relies on a few key vendors, with significant concentration in accounts payable and services rendered, posing supply chain and cost risks.
• Ongoing litigation with a former employee has an uncertain ultimate disposition or resolution, which could have an adverse impact.
• The ELOC facility includes a $250,000 termination fee if the company sells less than $7.5 million in shares and elects to terminate the agreement.
• The company has exceeded the permissible number of shares to be issued under the 2024 Equity Incentive Plan by 200,000 share awards, requiring an amended Form S-8 filing.

Future Outlook

The company's strategy involves leveraging core competitive strengths to develop and maintain ongoing customer relationships, grow service lines, and meet changing customer needs. It aims to be a premier provider of logistics and fulfillment services, offering disruptive solutions to older technologies like dry ice and liquid nitrogen in the life sciences industry. The company expects its operations to vary seasonally, with revenue typically highest in the third and fourth calendar quarters and lowest in the first and second, and operating expenses potentially higher during winter months due to adverse weather.

Management Comments

• Management believes the company's solutions are disruptive to older technologies of dry ice and liquid nitrogen, offering comprehensive, reliable, and economic alternatives for frozen shipping in the life sciences industry.
• Management aims to be recognized as the premier provider of logistics and fulfillment of a broad range of value-added services based upon breadth, quality, responsiveness, customer service, information technologies, safety, and cost effectiveness.
• Management believes that material losses arising from ongoing litigation with a former employee are not probable as of September 30, 2025.

Industry Context

Callan JMB operates in the vertically integrated logistics and fulfillment sector, specifically targeting the life sciences industry with thermal management solutions. The company emphasizes advanced predictive technology to ensure product integrity and immediate response for time-sensitive products. This positions it as a competitor to traditional cold chain methods, aiming to disrupt older technologies like dry ice and liquid nitrogen by offering comprehensive, customized, and environmentally responsible alternatives for cryogenic or frozen temperature requirements.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global industry benchmarks. Therefore, a direct comparison to industry standards is not feasible based solely on the provided information.

Corporate Governance

Legal Proceedings

• A demand letter from a vendor alleging breach of a Customer Service Agreement was settled in February 2025 for $240,800, which was paid.
• The company is subject to ongoing litigation by a former employee where the ultimate disposition or resolution is uncertain. Management believes material losses from this litigation are not probable as of September 30, 2025.

Related Party Transactions

• Provided labor services to Health Hero America (HHA), a related party, recognizing $42,624 in service revenue for the nine months ended September 30, 2025.
• Pays $9,800 per month to Outlaw Run Ranch (ORR), a related party, for rent expense.
• Leases its headquarters, warehouse, other warehouse equipment, and a box truck for $15,425 per month from Warehouse Asset Management, a related party.
• Advanced $18,669 to a director of the company in 2024, which was repaid in full in 2025.
• Awarded 100,000 stock options to the CEO's son as compensation for prior services, with 25,000 options vested as of September 30, 2025, and $72,073 recognized as expense for the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders face significant dilution risk from the Equity Line of Credit (ELOC) facility and potential future capital raises, alongside substantial net losses impacting shareholder value.
• Employees, particularly management, received significant stock-based compensation, but the overall financial performance and internal control deficiencies could impact employee morale and stability.
• Customers in emergency preparedness services saw decreased demand, while specialty packaging revenue also declined, indicating potential shifts in customer needs or market competition.
• Creditors and investors in the ELOC facility are exposed to the company's financial performance and stock price volatility, as the facility's terms are tied to VWAP.
• Regulatory bodies may scrutinize the company's internal control deficiencies, even if deemed not material weaknesses by management.

Next Steps

• File an amended Form S-8 to register shares to account for the overallotment under the 2024 Equity Incentive Plan, as the permissible number of shares has been exceeded by 200,000.

Key Dates

Recommendation

The company's financial performance is severely deteriorating, evidenced by a 438% increase in net loss and a significant negative shift in operating cash flow for the nine months ended September 30, 2025. While capital was raised through an IPO and an ELOC, these funds are being rapidly consumed by soaring operating expenses, which nearly doubled. The disclosure of ineffective internal controls, even if not deemed material weaknesses by management, raises serious concerns about financial reporting reliability and corporate governance. The reliance on dilutive capital raises to fund operations, coupled with declining revenue in key segments, suggests an unsustainable business model in its current state. These factors collectively point to substantial downside risk for investors.

Keywords

Callan JMB, CJMB, 10-Q, Quarterly Report, Financial Results, Logistics, Cold Chain, Life Sciences, SEC Filing, Equity Line of Credit, IPO, Net Loss, Operating Expenses, Stock-Based Compensation, Internal Controls, Supply Chain